AI assistant
H. Lundbeck A — Remuneration Information 2016
May 13, 2016
Preview isn't available for this file type.
Download source fileValby, Denmark, 2016-05-13 08:31 CEST (GLOBE NEWSWIRE) -- Valby, Denmark, 13
May 2016 - H. Lundbeck A/S (Lundbeck) hereby reports transactions made by
executives and persons and legal entities closely associated to them with
shares and linked securities in Lundbeck, cf. Section 28a of the Danish
Securities Trading Act.
On Lundbeck’s Annual General Meeting held on 31 March 2016, the shareholders
authorized the board of directors to offer the CEO to participate in the 2014
warrant program. In connection herewith, the Board of Directors has granted the
below warrants to the CEO, and the CEO has accepted to receive such warrants.
Each warrant grants the right to subscribe for one (1) share in Lundbeck. The
calculation of the market price of the warrants is based on Black-Scholes.
Name: Kåre Schultz
Job position: President and CEO
ID code (ISIN code): DK 0010287234
Name of the issuer of the securities: H. Lundbeck A/S
Description of the security: Warrants
Nature of the transaction: Grant of warrants
Date of trading (date of accept): 12 May 2016
Market on which the trading was affected: Nasdaq OMX Copenhagen
Number of traded securities (warrants granted): 400,000
Market price of securities traded (Black-Scholes): Approx. DKK 34.1 million
Persons under obligation to report such transactions are defined as members of
the Executive Management, members of the Board of Directors and other
executives of H. Lundbeck A/S and persons/entities closely associated to them.
Closely associated persons/entities could include but is not limited to:
• spouse or cohabitant
• children below the age of 18, provided that the executive is
the custody holder
• legal entities in which the executive has a controlling
influence
Lundbeck contacts
Investors: Media:
Palle Holm Olesen Mads Kronborg
Vice President, Investor Relations Senior Director, Corp. Communication
[email protected] [email protected]
+45 30 83 24 26 +45 36 43 30 00
About H. Lundbeck A/S
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
specialized in psychiatric and neurological disorders. For more than 70 years,
we have been at the forefront of research within neuroscience. Our key areas of
focus are depression, schizophrenia, Parkinson's disease and Alzheimer's
disease.
An estimated 700 million people worldwide are living with psychiatric and
neurological disorders and far too many suffer due to inadequate treatment,
discrimination, a reduced number of working days, early retirement and other
unnecessary consequences. Every day, we strive for improved treatment and a
better life for people living with psychiatric and neurological disorders – we
call this Progress in Mind.
Our approximately 5,300 employees in 55 countries are engaged in the entire
value chain throughout research, development, manufacturing, marketing and
sales. Our pipeline consists of several late-stage development programmes and
our products are available in more than 100 countries. We have research centres
in China and Denmark and production facilities in China, Denmark, France and
Italy. Lundbeck generated core revenue of DKK 14.6 billion in 2015 (EUR 2
billion; USD 2.2 billion).
For additional information, we encourage you to visit our corporate site
www.lundbeck.com and connect with us on Twitter at @Lundbeck.